20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                : Unlikely to be dialysed. Dose as in normal renal function
HD                     : Unlikely to be dialysed. Dose as in normal renal function
HDF/high flux   : Unknown dialysability. Dose as in normal renal function
CAV/VVHD      : Unlikely to be dialysed. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Antibacterials: toxicity increased by erythromycin – avoid concomitant use
Anti-epileptics: phenytoin levels may be reduced
Antifungals: metabolism possibly inhibited by posaconazole (increased risk of neurotoxicity)
Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis)
ADMINISTRATION
Reconstition
Add 10 mL of diluent to 10 mg vial. May be administered into fast-running drip of sodium chloride 0.9%
Route
IV
Rate of Administration
1 minute
Comments
Do not dilute with large volumes (e.g. 100–250 mL) or give over long periods (30–60 minutes) as thrombophlebitis and extravasation may occur
OTHER INFORMATION
Vinblastine is extensively metabolised (primarily in the liver) to desacetylvinblastine, which is more active than the parent compound. 33% of the drug is slowly excreted in the urine and 21% in the faeces within 72 hours